Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. ・The ...

Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched ...

Pfizer has taken a beating in recent years, and its market cap is now around $140 billion. But with the company still ...

Pharmaceutical companies have raised prices on hundreds of drugs so far this month despite federal efforts to rein in drug ...

Madrigal has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the intention of combining the drug with its ...

Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma company’s aging blockbusters. Late Friday, after a dramatic bidding war, he ...

Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap ...

The Trump administration and Pfizer PFE announced an agreement on Sept. 30 that includes most-favored-nation pricing for Pfizer’s drugs in Medicaid programs, discounts for direct sales of Pfizer drugs ...

We recently published 10 Stocks Jim Cramer Talked About. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer talked ...

WASHINGTON (AP) — Pfizer has agreed to lower the cost of prescription drugs for Medicaid under a deal struck with the Trump administration, President Donald Trump said Tuesday as he promised similar ...